Same Result, Different Price: Compounded versus Branded Tirzepatide

Same Result, Different Price: Compounded vs. Branded Tirzepatide

Is the cheaper version of a weight-loss drug actually a worse deal? Compounded tirzepatide is being prescribed at scale as a budget-friendly substitute for branded medications like Mounjaro and Zepbound. While the conversation usually centers on the massive price gap between the two, the real question isn't whether compounded is cheaper in the abstract. It is whether it is cheaper than the specific price a patient can actually afford.

A new study from researchers at the University of Colorado and Mochi Health investigates this tension. By analyzing real-world data, the authors attempt to determine if the two formulations produce comparable weight loss. They also examine how the "savings" of compounding fluctuate across different insurance and cash-pay tiers.

Beyond the sticker price

The central question driving this research is twofold. Do compounded and branded tirzepatide formulations yield similar clinical results? And how does the economic advantage of compounding change depending on a patient's access? The authors argue that existing arguments for compounded drugs are often built on a flawed premise. Most comparisons anchor the cost of branded tirzepatide to a high retail list price of roughly $1,000 to $1,200 per month.

However, the authors suggest this framing ignores the reality of the modern pharmaceutical landscape. Branded tirzepatide is currently sold through a wide distribution of price points. These range from low insurance copays (the fixed amount a patient pays for a prescription) of sometimes as low as $25. Other tiers include specialized direct-to-consumer programs like LillyDirect. Consequently, the study seeks to move away from a single "savings" figure. Instead, it treats cost-effectiveness as a function of a patient's specific financial access.

The flaw in raw comparisons

Before this study, many observers pointed to unadjusted data suggesting that branded tirzepatide outperformed compounded versions. However, the authors note that these gaps are likely artifacts of "selection bias." This occurs when the people receiving the branded drug are fundamentally different from those receiving the compounded version. For instance, patients with branded prescriptions are far more likely to have robust insurance coverage. This correlates with higher adherence (how consistently a patient takes their medicine) and different baseline health characteristics.

As shown in, the researchers utilized a Directed Acyclic Graph (DAG)—a visual tool used to map out causal relationships and identify potential "confounders" (hidden variables that might skew results).

Their model highlighted that factors like insurance status and baseline BMI are heavily linked to which formulation a patient receives. Without accounting for these differences, any comparison of weight loss would be comparing apples to oranges. Such a comparison would mistakenly attribute the advantages of a well-insured patient to the brand-name drug itself.

Disentangling drug from patient

To isolate the effect of the drug from the characteristics of the patient, the authors conducted a retrospective cohort study of 7,271 tirzepatide users. They employed 1:1 nearest-neighbor propensity-score matching. This is a statistical technique that creates pairs of patients who are nearly identical across several baseline metrics. These metrics included age, sex, BMI, and insurance status. This process effectively balances the groups. It ensures the comparison is as close to a controlled experiment as real-world data allows.

The investigators specifically focused on a six-month window of weight observation. They also carefully avoided adjusting for "mediators" (variables that sit on the causal path between the drug and the outcome). Examples include how strictly a patient follows their dosing schedule. These behaviors are themselves influenced by the choice of drug. By focusing only on baseline traits, the authors aimed to ensure that any observed difference in weight loss was due to the formulation rather than the patient's starting profile.

Statistical equivalence in weight loss

The results indicate that the two formulations are remarkably similar. The authors report that after matching, the mean percent body weight loss was 11.4% for branded users and 11.4% for compounded users .

Even when looking at the "response rate"—the proportion of patients achieving at least 10% weight loss—the difference was minimal. Specifically, the rate was 59.3% for branded vs. 57.2% for compounded.

Most importantly, the study found that these results were not just "not significantly different." They were statistically equivalent. Using a specialized test called Two One-Sided Tests (TOST), the authors confirmed the similarity. The difference in mean weight loss fell within a pre-specified clinical margin of ±2 percentage points . This suggests that, for the average user in this cohort, the choice between branded and compounded tirzepatide is not a choice between different levels of effectiveness.

A conditional economic reality

Since the effectiveness is equivalent, the decision becomes purely a matter of math. However, the "math" changes depending on which price tier a patient inhabits. The authors mapped out five different branded price scenarios to show how the cost advantage of compounding shifts .

In the "strong case"—where a patient pays the full retail list price—compounded tirzepatide saves an estimated $6,000 over six months .

In the "modest case," such as using LillyDirect's self-pay options, the savings are still real. However, they are notably smaller, ranging from $594 to $1,494 . Crucially, the authors found a "no case" regime. For patients with typical insurance copays of $150 or lower, the compounded version actually costs more than the branded drug .

The implication is that the "compounded is always cheaper" narrative is an oversimplification. For a significant portion of the population—specifically those with good insurance coverage—the branded drug remains the superior financial choice. For everyone else, particularly the uninsured or those with high deductibles, compounded tirzepatide provides a critical pathway to accessing therapy. A logical next step for researchers would be to validate these findings across different geographic regions or larger datasets.